Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Necrosis

ClinicalTrials.gov lists 3,934 trials for Necrosis or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 64.

MeSH D009336 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 95 Phase 1/2 Phase 1/2 65 Phase 2 Phase 2 252 Phase 2/3 Phase 2/3 72 Phase 3 Phase 3 312 Phase 4 Phase 4 420 Not applicable Not applicable 1,224 Observational Observational 1,489 Phase 1 Phase 1 95 Phase 1/2 Phase 1/2 65 Phase 2 Phase 2 252 Phase 2/3 Phase 2/3 72 Phase 3 Phase 3 312 Phase 4 Phase 4 420 Not applicable Not applicable 1,224 Observational Observational 1,489

Trials per phase (log scale)

2 more sections with rows

57 of the 3,934 trials are tagged with Necrosis itself; the rest are tagged with a narrower condition beneath it.

Get the Necrosis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Necrosis trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 5 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 220

1990: 2 trials (Observational 2) 1991: 8 trials (Observational 8) 1992: 6 trials (Observational 2, Phase 3 4) 1993: 4 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1) 1994: 9 trials (Observational 7, Phase 3 2) 1995: 12 trials (Observational 9, Phase 3 3) 1996: 2 trials (Phase 4 1, Phase 3 1) 1997: 11 trials (Observational 6, Not applicable 1, Phase 3 3, Phase 1/2 1) 1998: 14 trials (Observational 10, Phase 4 1, Phase 3 3) 1999: 17 trials (Observational 8, Not applicable 1, Phase 4 3, Phase 3 3, Phase 2 1, Phase 1 1) 2000: 20 trials (Observational 8, Not applicable 4, Phase 4 2, Phase 3 6) 2001: 37 trials (Observational 16, Not applicable 8, Phase 4 6, Phase 3 6, Phase 2/3 1) 2002: 32 trials (Observational 10, Not applicable 4, Phase 4 5, Phase 3 8, Phase 2 3, Phase 1 2) 2003: 73 trials (Observational 25, Not applicable 10, Phase 4 12, Phase 3 12, Phase 2/3 2, Phase 2 8, Phase 1/2 3, Phase 1 1) 2004: 61 trials (Observational 18, Not applicable 12, Phase 4 15, Phase 3 7, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2005: 80 trials (Observational 19, Not applicable 12, Phase 4 17, Phase 3 15, Phase 2/3 3, Phase 2 6, Phase 1/2 3, Phase 1 5) 2006: 105 trials (Observational 29, Not applicable 12, Phase 4 25, Phase 3 13, Phase 2/3 3, Phase 2 13, Phase 1/2 2, Phase 1 8) 2007: 106 trials (Observational 37, Not applicable 18, Phase 4 18, Phase 3 9, Phase 2/3 6, Phase 2 12, Phase 1/2 3, Phase 1 3) 2008: 93 trials (Observational 24, Not applicable 19, Phase 4 7, Phase 3 14, Phase 2/3 9, Phase 2 12, Phase 1/2 4, Phase 1 4) 2009: 114 trials (Observational 30, Not applicable 29, Phase 4 19, Phase 3 9, Phase 2/3 6, Phase 2 16, Phase 1/2 1, Phase 1 4) 2010: 119 trials (Observational 52, Not applicable 25, Phase 4 13, Phase 3 13, Phase 2/3 1, Phase 2 7, Phase 1/2 4, Phase 1 4) 2011: 158 trials (Observational 56, Not applicable 37, Phase 4 23, Phase 3 12, Phase 2/3 4, Phase 2 14, Phase 1/2 7, Phase 1 5) 2012: 138 trials (Observational 52, Not applicable 47, Phase 4 15, Phase 3 8, Phase 2 11, Phase 1/2 2, Phase 1 3) 2013: 136 trials (Observational 53, Not applicable 41, Phase 4 11, Phase 3 14, Phase 2/3 3, Phase 2 9, Phase 1/2 1, Phase 1 4) 2014: 176 trials (Observational 73, Not applicable 50, Phase 4 24, Phase 3 10, Phase 2/3 2, Phase 2 12, Phase 1/2 1, Phase 1 4) 2015: 185 trials (Other 2, Observational 70, Not applicable 51, Phase 4 26, Phase 3 9, Phase 2/3 3, Phase 2 11, Phase 1/2 7, Phase 1 6) 2016: 162 trials (Observational 52, Not applicable 70, Phase 4 18, Phase 3 6, Phase 2/3 2, Phase 2 8, Phase 1/2 4, Phase 1 2) 2017: 195 trials (Observational 77, Not applicable 71, Phase 4 24, Phase 3 5, Phase 2/3 2, Phase 2 10, Phase 1/2 1, Phase 1 5) 2018: 194 trials (Observational 82, Not applicable 63, Phase 4 21, Phase 3 10, Phase 2/3 3, Phase 2 11, Phase 1/2 3, Phase 1 1) 2019: 180 trials (Observational 84, Not applicable 59, Phase 4 10, Phase 3 12, Phase 2/3 2, Phase 2 8, Phase 1/2 1, Phase 1 4) 2020: 187 trials (Observational 88, Not applicable 62, Phase 4 13, Phase 3 9, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 1) 2021: 208 trials (Observational 79, Not applicable 75, Phase 4 20, Phase 3 17, Phase 2/3 3, Phase 2 8, Phase 1/2 4, Phase 1 2) 2022: 211 trials (Observational 83, Not applicable 85, Phase 4 16, Phase 3 6, Phase 2/3 3, Phase 2 11, Phase 1/2 2, Phase 1 5) 2023: 220 trials (Observational 83, Not applicable 101, Phase 4 13, Phase 3 9, Phase 2/3 2, Phase 2 7, Phase 1/2 1, Phase 1 4) 2024: 195 trials (Observational 75, Not applicable 85, Phase 4 8, Phase 3 10, Phase 2/3 2, Phase 2 11, Phase 1/2 1, Phase 1 3) 2025: 208 trials (Observational 76, Not applicable 84, Phase 4 14, Phase 3 13, Phase 2/3 1, Phase 2 13, Phase 1/2 3, Phase 1 4)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 197
2025 208
2024 195
2023 220
2022 211
2021 208
2020 187
2019 180
2018 194
2017 195

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 220 trials starting in 2026 and about 210 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 279 trials still running at the 2026-10-09 snapshot; registered median of 29 months across 2,134 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Necrosis trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 95
Phase 1/2 65
Phase 2 252
Phase 2/3 72
Phase 3 312
Phase 4 420
Not applicable 1,224
Observational 1,489
Expanded access 3
Unknown 2

How many Necrosis trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 198
Recruiting 461
Enrolling by invitation 35
Active, not recruiting 161
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Necrosis trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 64
Zimmer Biomet 49
AstraZeneca 18

Which drugs are being tested for Necrosis? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
ATORVASTATIN 23
Tenecteplase 17
Rivaroxaban 16
Abciximab 16
BMS-512148 15

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ticagrelor (Brilique) 90 63
Clopidogrel 75 56
EC Aspirin 54
Prasugel 26
Colchicines 22

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Necrosis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Other 16,735 7
MVE 6,060 1
Pneumonia 3,007 61
Hospitalization 1,855 2
Angina pectoris 1,645 41

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Necrosis? (862)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. British journal of cancer 2021 Yes
Necrotizing soft tissue infections - a multicentre, prospective observational study (INFECT): protocol and statistical analysis plan. Acta anaesthesiologica Scandinavica 2018 Yes
Depth of Cervical Intraepithelial Neoplasia Grade 3 in Peruvian Women: Implications for Therapeutic Depth of Necrosis. Journal of lower genital tract disease 2018 Yes
Bevacizumab Monotherapy Reduces Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma Patients: A Randomized Controlled Trial. International journal of radiation oncology, biology, physics 2018 Yes
Necroptosis: a regulated inflammatory mode of cell death. Journal of neuroinflammation 2018 Yes

Showing 5 of 862 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages